Inhibitors of human mitotic kinesin Eg5: Characterization of the 4-phenyl-tetrahydroisoquinoline lead series
Tarby, C.M., Kaltenbach III, R.F., Huynh, T., Pudzianowski, A., Shen, H., Ortega-Nanos, M., Sheriff, S., Newitt, J.A., McDonnell, P.A., Burford, N., Fairchild, C.R., Vaccaro, W., Chen, Z., Borzilleri, R.M., Naglich, J., Lombardo, L.J., Gottardis, M., Trainor, G.L., Roussell, D.L.(2006) Bioorg Med Chem Lett 16: 2095-2100
- PubMed: 16458511 
- DOI: https://doi.org/10.1016/j.bmcl.2006.01.056
- Primary Citation of Related Structures:  
2FME - PubMed Abstract: 
In a high-throughput screening effort, a series of tetrahydroisoquinolines was identified as modest inhibitors of human Eg5. A medicinal chemistry optimization effort led to the identification of R-4-(3-hydroxyphenyl)-N,N-7,8-tetramethyl-3,4-dihydroisoquinoline-2(1H)-carboxamide (32a) as a potent inhibitor of human Eg5 (ATPase IC50 104 nM) with good anti-proliferative activity in A2780 cells (IC50 234 nM).
Organizational Affiliation: 
Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, USA. christine.tarby@bms.com